Krötenwanderung im Frühling Alljährlich im März, wenn die Temperaturen nicht mehr unter Null sinken, erleiden viele unserer heimischen Amphibien den Krötentod. Auf ihren Wanderungen zu ihrem Laichgewässer müssen diese Tiere immer öfter viel befahrene Straßen überqueren. Für etliche Kröten, Frösche und Molche ein russisches Roulette. Als häufigste Amphibienart ist unsere heimische Erdkröte davon betreffen. Deshalb spricht man landläufig auch nur von Krötenwanderung oder Krötentod im Frühling.  

Alljährlich im März, wenn die Temperaturen nicht mehr unter Null sinken, erleiden viele unserer heimischen Amphibien den Krötentod. Auf ihren Wanderungen zu ihrem Laichgewässer müssen diese Tiere immer öfter viel befahrene Straßen überqueren. #Amph
https://www.tberg.de/kroetenwanderung-im-fruehling/

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q4 2025 net revenues of $183.1M and fiscal 2025 net revenues of $719.9M. GAAP net income was $24.4M in Q4 and $98.1M for the year; GAAP diluted EPS was $0.51 and $2.03, respectively. Adjusted non-GAAP net income was $34.2M for Q4 and $156.6M for the year. BAQSIMI drove double-digit growth, iron sucrose and teriparatide received FDA approvals, R&D and G&A rose due to clinical programs, ERP and a $23.1M legal settlement. Cash flow from operations was $156.1M.

#AMPH Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

www.stocktitan.net/news/AMPH/amphastar-phar...

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditionsRANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the

#AMPH Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

www.stocktitan.net/news/AMPH/amphastar-phar...

Amphastar Wins FDA Approval for Teriparatide Injection, Expanding U.S.-Made Osteoporosis Portfolio Amphastar Pharmaceuticals (Nasdaq: AMPH) has received U.S. Food and Drug Administration approval for its teriparatide injection, marking a notable milestone as

Amphastar (NASDAQ: #AMPH) wins FDA approval for its teriparatide injection, a generic alternative to FORTEO®, with U.S.-based manufacturing and a planned launch by year-end.

prismmarketview.com/amphastar-wi...

#AMPH Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025

www.stocktitan.net/news/AMPH/amphastar-phar...

Hopkinton Episode 2 page 15-16 #Hopkinton #amph

Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Amphastar Pharmaceuticals (NASDAQ:AMPH) has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology for three proprietary peptides in the US and Canada. The agreement includes an initial payment of $6 million ($0.75M earnest money + $5.25M upfront), with potential milestone payments reaching $453 million over the agreement's lifetime.The licensed products include: 1) An endogenous peptide targeting multiple poorly treated cancers, 2) A novel peptide-docetaxel conjugate designed to improve taxane therapies, and 3) An anti-VEGFR peptide eye drop for wet age-related macular degeneration treatment. The agreement includes 5% royalty payments on net sales, capped at $60 million per Licensed Product.

#AMPH Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.

www.stocktitan.net/news/AMPH/amphastar-phar...

Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga, California headquarters. The company plans to quadruple its production capacity over the next 3-5 years, marking its largest domestic infrastructure investment to date.The expansion includes a new state-of-the-art production plant, enhanced automation, and advanced technologies integration to support critical medication production and pipeline candidates. The initiative will create new jobs across R&D, engineering, manufacturing, and quality operations. Notably, all of Amphastar's finished pharmaceutical products are manufactured in the U.S., reinforcing their commitment to domestic production and supply chain resilience.

#AMPH Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters

www.stocktitan.net/news/AMPH/amphastar-phar...

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2025 financial results with net revenues of $170.5M, slightly down 1% from $171.8M in Q1 2024. GAAP net income was $25.3M ($0.51 per share), compared to $43.2M ($0.81 per share) in Q1 2024. BAQSIMI® sales surged 177% to $38.4M, while Primatene MIST® grew 20% to $29.1M. However, Glucagon and Epinephrine sales declined 27% and 29% respectively due to increased competition. The company's pipeline includes 4 ANDAs and 1 biosimilar insulin candidate filed with FDA, targeting products with >$3B market size. The FDA's acceptance of AMP-004 insulin biosimilar application marks a significant milestone for their biosimilar portfolio expansion.

#AMPH Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

www.stocktitan.net/news/AMPH/amphastar-phar...

Amphastar Wins FDA Award: How Its Solution to Critical Drug Shortage Signals Major Growth Subsidiary earns FDA recognition for epinephrine shortage solution. Pipeline targets $10.3B market with ANDAs, biosimilars, and proprietary products. Full analysis inside.

#AMPH International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

www.stocktitan.net/news/AMPH/international-...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks oversold with improving relative strength, Mon Feb 24th - #ATCH #RETO #ODP #AMPH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

News; ( NASDAQ: #AMPH ) Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

#AMPH Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/AMPH/amphastar-phar...

#AMPH Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

www.stocktitan.net/news/AMPH/amphastar-phar...